ReviewCancers2022
Current and Developing Liquid Biopsy Techniques for Breast Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Surface-Enhanced Raman Spectroscopy in Breast Cancer Detection: A Bibliometric Review and Landscape of Global Trends.Biosensors · 2026Review
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Article
- Artificial Intelligence-Based Exosome Analysis for Improving Diagnostic Performance of Breast Lesions on Ultrasound: Protocol of a Prospective, Multicenter Cohort Study.Journal of breast cancer · 2026Article
- MicroRNAs in Breast Cancer: Diagnostic and Prognostic Potential, Challenges, and Clinical Reliability.Biomedicines · 2026Review
- Liquid biopsy in breast cancer: current biomarker platforms and clinical applications.Exploration of targeted anti-tumor therapy · 2026Review
- Discovery of Landscape Phage Probes Against Cellular Communication Network Factor 1 (CCN1/Cyr61).Viruses · 2025Article
- Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer.Expert reviews in molecular medicine · 2025Review
- Oxygen deprivation in breast cancer: mechanisms, pathways, and implications.Annals of medicine and surgery (2012) · 2025Review
- microRNAs as Biomarkers of Breast Cancer.International journal of molecular sciences · 2025Review
- High frequency of the PIK3CA H1047L mutation in Indonesian breast cancer across molecular subtypes.PloS one · 2025Article
- Exploring Prognostic Gene Factors in Breast Cancer via Machine Learning.Biochemical genetics · 2024Article
- Predictive models and biomarkers for survival in stage III breast cancer: a review of clinical applications and future directions.Annals of medicine and surgery (2012) · 2024Review
- From Biosensors to Robotics: Pioneering Advances in Breast Cancer Management.Sensors (Basel, Switzerland) · 2024Review
- Article
- The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics.Frontiers in genetics · 2024Review
- Diagnostic value of 5 miRNAs combined detection for breast cancer.Frontiers in genetics · 2024Article
- Review
- The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women.Journal of cancer research and clinical oncology · 2023Article
- CNT and Graphene-Based Transistor Biosensors for Cancer Detection: A Review.Biomolecules · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Breast cancer is the most commonly diagnosed cancer and leading cause of cancer mortality among woman worldwide. The techniques of diagnosis, prognosis, and therapy monitoring of breast cancer are critical. Current diagnostic techniques are mammography and tissue biopsy; however, they have limitations. With the development of novel techniques, such as personalized medicine and genetic profiling, liquid biopsy is emerging as the less invasive tool for diagnosing and monitoring breast cancer. Liquid biopsy is performed by sampling biofluids and extracting tumor components, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free mRNA (cfRNA) and microRNA (miRNA), proteins, and extracellular vehicles (EVs). In this review, we summarize and focus on the recent discoveries of tumor components and biomarkers applied in liquid biopsy and novel development of detection techniques, such as surface-enhanced Raman spectroscopy (SERS) and microfluidic devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.